Synexa Insights
The Latest Insights From Our Scientists
Establishing Biosimilarity: Regulatory and Scientific Expectations
A biosimilar is defined as a biologic product, highly similar to a reference or originator, with no clinically meaningful differences in terms of safety, purity,…
Why The Future Of Precision Medicine Will Be Defined By The Quality And Strategy Of Biomarker Signatures
We’re in the midst of a paradigm shift in biomarker science. No longer academic luxuries or exploratory afterthoughts, biomarker signatures…
Radiopharmaceutical Drug Development: A Bioanalytical Lab Perspective
The radiopharmaceutical industry has traditionally experienced steady but modest growth, primarily driven by its established role in diagnostics and nuclear…
Building a bioanalytical workflow for a vaccine study: The key assays and considerations
The COVID-19 pandemic put vaccines under the spotlight again, and from a scientific perspective at least, innovations have abounded.…
Quantitative Analysis of Oligonucleotides: An out of the box LC-MS/MS approach
Oligonucleotide therapeutics have revolutionised the field of medicine over the last decade due to their potential for treating a broad…
The Next Frontier for CAR T-Cell Therapy: Shifting Gears to Autoimmune Conditions
CAR T-cell therapy has transformed cancer treatment, offering new hope for patients with aggressive B cell malignancies like acute lymphoblastic…
Identifying biomarkers of success: Integrated bioanalysis for glioblastoma CAR-T cell clinical trials
Glioblastoma remains one of the most aggressive and treatment-resistant cancers. Standard therapies often fail, leaving patients with limited options.…
Allogeneic CAR T cell therapies: A major step forward
In a groundbreaking clinical trial, three individuals suffering from severe autoimmune diseases have entered remission following a novel CAR T…
A controlled detonation: Targeted antibody drug conjugates (ADCs) for oncology
Are antibody-drug conjugates (ADCs), principally comprised of an antibody, a cytotoxic payload and a linker, the next therapeutic modality of…
The mpox outbreak: Variants, transmission and the boost for vaccine manufacturers
Following Covid-19, the world is collectively on high alert for anything that could indicate another pandemic. What do we know…
The STING in the tail: How our own defense mechanisms to infection may be working against us
In this latest blog, we explore this pathway, its burgeoning links to multiple diseases and how biomarker profiling can assist…
Falling drug approval rates: What should we be doing differently?
Over the years, this failure rate of drug approvals has not seen significant improvement, which begs the question - why?…
Patient Derived Organoids: Shaping the Fight Against Paediatric Brain Cancer
We highlight some of the exciting translational tools that have been developed to understand brain cancer and how these are…
Improving the quality of human health
Contact us
Discuss biomarker and bioanalytical solutions to accelerate your therapeutic pipeline
